News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • The United States and Iran agreed to a two-week ceasefire, reopening prospects for tanker traffic through the Strait of Hormuz.
  • Brent and WTI oil prices plunged more than 13% after the ceasefire.
  • U.S. equity futures rose sharply while U.S. defense shares slid amid the truce and lower war-funding expectations.
  • Investors boosted Fed-cut odds for year-end and bond yields moved lower.
  • Exxon expects up to $2.9 billion in Q1 upstream gains but flagged a roughly $5.3 billion near-term downstream timing hit.
  • Shell warned of weaker gas output and tighter near-term liquidity, saying oil trading partly offsets the impact.
  • The 30-year mortgage rate fell to 6.51% as purchase demand remained soft and applications stayed below year-ago levels.

Latest Articles

KeyBanc Keeps Sector Weight on Avista After 2025 RFP Selections; Capital Plan, Rate Filing Highlight Path Forward

KeyBanc Keeps Sector Weight on Avista After 2025 RFP Selections; Capital Plan, Rate Filing Highlight Path Forward

KeyBanc has reaffirmed a Sector Weight rating on Avista (AVA) after the utility announced the winners of its 2025 Request for Proposals. The selected portfolio, which combines company-owned resources and power purchase agreements, is expected to drive $250 million to $350 million of incremental capital and may support an uplift to Avista's long-ter…

FDA Lifts Hold on Intellia’s Nerve-Disease Gene Therapy Trial, Enabling Restart of Patient Enrollment

FDA Lifts Hold on Intellia’s Nerve-Disease Gene Therapy Trial, Enabling Restart of Patient Enrollment

The U.S. regulator has lifted a clinical hold on Intellia Therapeutics’ late-stage trial of its CRISPR-based therapy, nexiguran ziclumeran, in patients with hereditary transthyretin amyloidosis with polyneuropathy (ATTRv-PN). Intellia said it will resume patient enrollment as soon as possible after agreeing to enhanced safety monitoring measures. A…

HSBC Advises Investors to Maintain Aggressive Risk-On Posture

HSBC Advises Investors to Maintain Aggressive Risk-On Posture

HSBC is urging clients to stay positioned for further gains in risk assets, remaining overweight equities, high-yield credit, emerging-market debt and gold, while underweighting developed-market sovereigns, investment-grade credit and oil. The bank says geopolitics is secondary to U.S. rates, rates volatility and near-term growth expectations, and …

TSX Futures Inch Up as Commodities Gain; Markets Await Fed, BoC Decisions

TSX Futures Inch Up as Commodities Gain; Markets Await Fed, BoC Decisions

Futures tied to Canada’s primary stock index moved modestly higher as gains in gold and silver helped offset other headwinds. Investors are positioning ahead of Federal Reserve and Bank of Canada policy meetings, with U.S. futures trading mixed and commodities - notably gold and crude - showing notable strength amid trade tensions and severe winter…

CoStar Shares Rally After Third Point Reveals Plans for Activist Push

CoStar Shares Rally After Third Point Reveals Plans for Activist Push

CoStar Group shares jumped after billionaire investor Daniel Loeb’s hedge fund, Third Point, signaled plans for an activist campaign at the real estate data company. The fund intends to nominate multiple directors to CoStar's eight-person board and push management to concentrate on commercial real estate while divesting or shutting down recently ex…

Piper Sandler Sticks With Overweight on Stryker Ahead of Q4 Results, Sees Upside From New Handheld Robot

Piper Sandler Sticks With Overweight on Stryker Ahead of Q4 Results, Sees Upside From New Handheld Robot

Piper Sandler has maintained an Overweight rating and a $420 price target on Stryker, positioning the stock for roughly 18% upside from its current level as the company prepares to report fourth-quarter results. The firm cites a newly previewed handheld orthopedic robot - identified as Mako RPS after patent review and physician feedback - as a pote…